Rilpivirine: A new addition to the anti-HIV-1 armamentarium

Drugs of Today

Volumn 47, Issue 1, 2011, Pages 5-15

  Miller, C D ^a   Crain, J ^a   Tran, B ^a   Patel, N ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FAMOTIDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; RILPIVIRINE; TENOFOVIR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; LIPID BLOOD LEVEL; LONG TERM CARE; LOW DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; PHENOTYPE; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIROLOGY; VIRUS ISOLATION; VIRUS LOAD; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; NITRILES; PYRIMIDINES;

EID: 79955570951     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.1.1583188     Document Type: Review

References (48)

1. Bucher, H.C., Wolbers, M., Porter, K. 2010 guidelines for antiretroviral treatment of HIV from the International AIDS Society-USA Panel. JAMA 2010, 304(17): 1897.
2. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. U.S. Department of Health and Human Services, December 1, 2009. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed August 30, 2010.
3. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010, 50(10): 1387-96.
4. Harrison, K.M., Song, R., Zhang, X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr 2010, 53(1): 124-30.
5. Lewden, C., the Mortality Working Group of COHERE. Time with GDA cell count above 500 cells/mm3 allows HIV-infected men, but not women, to reach similar mortality rates to those of the general population: a 7-year analysis. 17th Conf Retroviruses Opportunistic Infect (CROI) (Feb 16-19, San Francisco) 2010, Abst 527.
6. May, M., Sterne, J.A., Sabin, C. et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007, 21(9): 1185-97. (Pubitemid 46763289)
7. van Sighem Gras, L., Reiss, P., Brinkman, K., de Wolf, F., ATHENA Natl Observational Cohort Study. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. 17th Conf Retroviruses Opportunistic Infect (CROI) (Feb 16-19, San Francisco) 2010, Abst 526.
8. Zwahlen, M., Harris, R., May, M. et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009, 38(6): 1624-33.
9. Haubrich, R.H., Riddler, S.A., DiRienzo, A.G. et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009, 23(9): 1109-18.
10. Perez-Molina, J.A. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials 2002, 3(4): 279-86.
11. Pozniak, A.L., Gallant, J.E., DeJesus, E. et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr 2006, 43(5): 535-40. (Pubitemid 44885619)
12. van Leth, F., Phanuphak, P., Ruxrungtham, K. et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004, 363(9417): 1253-63. (Pubitemid 38496486)
13. Weiser, S.D., Guzman, D., Riley, E.D., Clark, R., Bangsberg, D.R. Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV Clin Trials 2004, 5(5): 278-87. (Pubitemid 39545400)
14. Atripla approval in Europe. AIDS Patient Care STDS 2006, 20(12): 887.
15. A once-daily combination tablet (Atripla) for HIV. Med Lett Drugs Ther 2006, 48(1244): 78-9.
16. Killingley, B., Pozniak, A. The first once-daily single-tablet regimen for the treatment of HIV-infected patients. Drugs Today (Barc) 2007, 43(7): 427-42. (Pubitemid 47344920)
17. Das, K., Bauman, J.D., Clark, A.D., Jr. et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A 2008, 105(5): 1466-71. (Pubitemid 351346537)
18. Miller, V., de Bethune, M.P., Kober, A. et al. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother 1998, 42(12): 3123-9. (Pubitemid 28553729)
19. Antinori, A., Zaccarelli, M., Cingolani, A. et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002, 18(12): 835-8. (Pubitemid 35034664)
20. Brenner, B., Turner, D., Oliveira, M. et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003, 17(1): F1-5.
21. Arasteh, K., Rieger, A., Yeni, P. et al. Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy. Antivir Ther 2009, 14(5): 713-22.
22. Guillemont, J., Pasquier, E., Palandjian, P. et al. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J Med Chem 2005, 48(6): 2072-9. (Pubitemid 40396334)
23. Katlama, C., Clotet, B., Mills, A. et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther 2010, 15(7): 1045-52.
24. Mordant, C., Schmitt, B., Pasquier, E. et al. Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains. Eur J Med Chem 2007, 42(5): 567-79. (Pubitemid 46729579)
25. Cohen, C., Molina, J.M., Cahn, P. et al. Pooled week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, phase III trials comparing TMC278 versus efavirenz in treatment-naive, HIV-1-infected patients. 18th Int AIDS Conf (July 18-23, Vienna) 2010, Abst THLBB206.
26. Jena, A., Sachdeva, R.K., Sharma, A., Wanchu, A. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study. J Int Assoc Physicians AIDS Care (Chic III) 2009, 8(5): 318-22.
27. Sanne, I., Mommeja-Marin, H., Hinkle, J. et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005, 191(6): 825-9. (Pubitemid 40349795)
28. Gilead Sciences submits New Drug Application to U.S. FDA for once-daily single-tablet regimen of Truvada and TMC278 for HIV [news release]. Gilead Sciences, November 23, 2010. http://www.gilead.com/pr-1499754. Accessed January 25, 2010.
29. Ding, J., Das, K., Tantillo, C. et al. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution. Structure 1995, 3(4): 365-79.
30. Janssen, P.A., Lewi, P.J., Arnold, E. et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethyl-phenyl] amino]-2-pyrimidinyl] amino]benzonitrile (R278474, rilpivirine). J Med Chem 2005, 48(6): 1901-9.
31. Lansdon, E.B., Brendza, K.M., Hung, M. et al. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC25) and rilpivirine (TMC278): implications for drug design. J Med Chem 2010, 53(10): 4295-9.
32. Das, K., Clark, A.D., Jr., Lewi, P.J. et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etrovirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004, 47(10): 2550-60. (Pubitemid 38580092)
33. de Bethune, M.-P., Andries, K., Azijn, H. et al. TMC278, a new potent NNRTI with an increased barreir to resistance and good pharmacokinetic profile. 12th Conf Retroviruses Opportunistic Infect (Feb 22-25, Boston) 2005, Poster 556.
34. Goebel, F., Yakovlev, A., Pozniak, A.L. et al. Short-term antiviral activity of TMC278 - a novel NNRTI - in treatment-naive HIV-1-infected subjects. AIDS 2006, 20(13): 1721-6. (Pubitemid 44299363)
35. Hoetelmans, R., Kestens, D., Marièn, K. et al. Effect of food and multiple-dose pharmacokinetics of TMC278 as an oral tablet formulation: healthy volunteers. 3rd IAS Conf HIV Pathogenesis Treat (July 24-27, Rio de Janeiro) 2005, Abst TuPe3.1B10.
36. Van Heeswijk, R., Hoetelmans, R., Kestens, D. et al. The pharmacokinetic (PK) interaction between famotidine and TMC278, a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI), in HIV-negative volunteers. 4th IAS Conf HIV Pathog Treat Prev (July 22-25, Sydney) 2007, Abst TUPDB01.
37. Schöller-Gyüre, M., Debroye, C., Vyncke, V. et al. The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational, non-nucleoside reverse transcriptase inhibitor (NNRTI). 7th Int Workshop Clin Pharmacol HIV Ther (April 20-22, Lisbon) 2006, Abst 45.
38. Hoetelmans, R., Kestens, D., Stevens, M. et al. Pharmacokinetic interaction between the novel non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 and tenofovir disoproxil fumarate (TDF) in healthy volunteers. 6th lnt Workshop Clin Pharmacol HIV Ther (April 28-30, Quebec) 2005, Abst 18.
39. Van Heeswijk, R.P., Hoetelmans, R.M., Kestens, D. et al. The pharmacokinetic interaction between ketoconazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor in healthy, HIV-negative subjects. 16th Int AIDS Conf (Aug 13-18, Toronto) 2006, Abst TUPE0087.
40. Van Heeswijk, R.P.G., Hoetelmans, R.M.W., Aharchi, F. et al. The pharmacokinetic (PK) interaction between atorvastatin (AVS) and TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), in HIV-negative volunteers. 11th Eur AIDS Conf (Oct 24-27, Madrid) 2007, Abst P4.3/04.
41. Pozniak, A.L., Morales-Ramirez, J., Katabira, E. et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 2010, 24(1): 55-65.
42. Rimsky, L., Eron, J., Clotet, B. et al. Characterization of the resistance profile of TMC278: 48-week analysis of the phase 3 studies ECHO and THRIVE. 50th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 12-15, Boston) 2010, Abst H-1810.
43. Crauwels, H., Heeswijk, R., McNeeley, D. et al. Relative bioavailability of a concept pediatric formulation of TMC278, an investigational NNRTI. 18th Int AIDS Conf (July 18-23, Vienna) 2010, Abst THPE0158.
44. van 't Klooster, G., Hoeben, E., Borghys, H., Looszova, A., Bouche, M.P., van Velsen, F., Baert, L. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother 2010, 54(5): 2042-50.
45. Verloes, R., Klooster, G., Baert, L. TMC278 long acting - a parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers. 17th Int AIDS Conf (Aug 3-8, Mexico City) 2008, Abst TUPE0042.
46. Flandre, P., Peytavin, G., Meiffredy, V. et al. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial. Antivir Ther 2002, 7(2): 113-21. (Pubitemid 36427152)
47. Tuldra, A., Fumaz, C.R., Ferrer, M.J. et al. Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000, 25(3): 221-8. (Pubitemid 32010124)
48. Grover, S.A., Coupal, L., Gilmore, N., Mukherjee, J. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol 2005, 95(5): 586-91. (Pubitemid 40255245)